Akero Therapeutics Inc. (NASDAQ: AKRO) stock jumped 0.02% on Monday to $52.25 against a previous-day closing price of $52.24. With 1.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $52.69 whereas the lowest price it dropped to was $50.78. The 52-week range on AKRO shows that it touched its highest point at $58.38 and its lowest point at $25.21 during that stretch. It currently has a 1-year price target of $68.29. Beta for the stock currently stands at -0.94.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKRO was up-trending over the past week, with a rise of 5.83%, but this was up by 15.50% over a month. Three-month performance dropped to -4.30% while six-month performance rose 29.88%. The stock gained 96.95% in the past year, while it has lost -4.65% so far this year. A look at the trailing 12-month EPS for AKRO yields -2.56 with Next year EPS estimates of -3.35. For the next quarter, that number is -0.69. This implies an EPS growth rate of 0.70% for this year and -21.80% for next year.
Float and Shares Shorts:
At present, 51.87 million AKRO shares are outstanding with a float of 48.18 million shares on hand for trading. On Aug 30, 2023, short shares totaled 6.33 million, which was 11.39% higher than short shares on Jul 30, 2023. In addition to AYRO as the firm’s AYRO, Inc., AKRO serves as its Akero Therapeutics, Inc.
Institutional Ownership:
Through their ownership of 87.71% of AKRO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 57.29% of AKRO, in contrast to 37.39% held by mutual funds. Shares owned by individuals account for 27.10%. As the largest shareholder in AKRO with 7.92% of the stake, Janus Henderson Investors US LLC holds 4,403,909 shares worth 4,403,909. A second-largest stockholder of AKRO, Alkeon Capital Management LLC, holds 3,467,380 shares, controlling over 6.24% of the firm’s shares. T. Rowe Price Associates, Inc. is the third largest shareholder in AKRO, holding 3,249,134 shares or 5.84% stake. With a 2.96% stake in AKRO, the ACAP Strategic Fund is the largest stakeholder. A total of 1,644,987 shares are owned by the mutual fund manager. The T Rowe Price New Horizons Fund, which owns about 2.77% of AKRO stock, is the second-largest Mutual Fund holder. It holds 1,539,990 shares valued at 76.43 million. Vanguard Total Stock Market ETF holds 2.68% of the stake in AKRO, owning 1,492,385 shares worth 74.07 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, AKRO reported revenue of $0.00 and operating income of -$27.59M. The EBITDA in the recently reported quarter was -$27.34M and diluted EPS was -$0.77.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKRO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKRO analysts setting a high price target of $83.00 and a low target of $59.00, the average target price over the next 12 months is $67.50. Based on these targets, AKRO could surge 58.85% to reach the target high and rise by 12.92% to reach the target low. Reaching the average price target will result in a growth of 29.19% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded AKRO stock several times over the past three months with 5 Buys and 10 Sells. In these transactions, 132,500 shares were bought while 104,126 shares were sold. The number of buy transactions has increased to 39 while that of sell transactions has risen to 101 over the past year. The total number of shares bought during that period was 719,424 while 2,630,982 shares were sold.
